Current Status of Small Cell Lung Cancer in China - Abstract
In China, Small Cell Lung Cancer (SCLC) accounts for over 15% of lung cancers. Until now, the morbidity of SCLC has been increasing due to the ineffective smoking cession in China. Following the Chinese Guidelines of SCLC, the treatment of SCLC in China has been getting more and more standardized, which leads to the mortality of Chinese SCLC reaching the worldwide average. Although the outcomes of patients with SCLC has been limited improved, the Chinese scholars have made many attempts for the treatment of SCLC including emphasizing lung screening, accurate disease staging, multidisciplinary team-work, as well as actively translational medical research. Multicenter clinical studies regarding to amrubicin hydrochloride, lobaplatin, endostar and ipilimumab have been launched, as well as controversial problems for radiotherapy and surgery on SCLC. In addition, translational medicine researches on Circulating Tumor Cells (CTCs), Myeloid Suppression Cells (MDSCs) and next generation sequencing have been conducted to explored novel drive genes and prognostic markers of SCLC, which will provide more evidence to guide the diagnosis and treatment of SCLC.